DOPAMINERGIC TREATMENT OF TREATMENT REFRACTORY MOOD DISORDERS


Jan Fawcett, M.D.

Professor of Psychiatry
University of New Mexico School of Medicine

Conflicts:

More enjoyment than facts ...

...on Amazon!



ABBREVIATIONS		
BPD	Borderline Personality Disorder	
DSM-V	Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition	
ECT	Electroconvulsive therapy	
MAOI	Monoamine oxidase inhibitors	
MDD	Major depressive disorder	
NGA	New generation antidepressants	
NNT	Number needed to treat	
OCD	Obsessive-Compulsive Disorder	
PPX	Pramipexole	
SNRI	Serotonin–norepinephrine reuptake inhibitors	
SSRI	Selective serotonin reuptake inhibitors	
SUD	Substance use disorder	
TCA	Tricyclic antidepressants	
TRD	Treatment-resistant depression	
VNS	Vagus nerve stimulation	

Failed Remission and High Relapse Rates Are Common in Mood Disorders

MAJOR DEPRESSION: STAR*D OUTCOMES:


 $Sequenced \textit{Treatment Alternatives to Relieve Depression} \, (\textit{STAR*D}) \, was \, a \, collaborative \, study \, on \, the \, treatment \, of \, depression, \, funded \, by \, the \, National \, Institute \, of \, Mental \, Health$


Treatment step 1 — citalopram	36.8 % remission
Overall Remission Rates steps 1-4	67%
Treatment Resistant	33% after four steps of treatment

BUT


Four Month Recurrence rates step 1-4	40.2%-71%
Recovery rates	67% x 60% = 40.2% "Recovered" at 4 months


Recovery: no episode of depression for 6 months; recovery is a more reliable outcome than remission Recurrence: an episode of MDD after six months – assumed to be a "new" episode.








Would Dopaminergic Medications Help? Aripiprazole Pramipexole (PPX) Bupropion Modafinil Stimulants (Abilify) •22% affinity for •partial dopamine •unknown full •Dextro-amphetamine, dopamine transporter agonist – augments ADMs. mechanism, some Methylphenidate agonist – increases dopamine tonic levels. increase in increase by surge •very weak - common dopaminergic function. •Was used in Parkinson's •Two studies – did not Disease for motor symptoms – 2nd to loss of dopamine neurons. exceed placebo when added to SSRIs •Was found to benefit depression (particularly anhedonia - inability to pursue and enjoy usual pleasures). •Found effective in depression without Parkinson's Disease •PPX is off -patent (was Mirapex) – not marketed. • must be used carefully, dosed according to age (older people seem to tolerate and require higher doses) • can cause nausea, sleepiness, sex/gambling addiction. • if stopped rapidly can cause DAWS (Dopamine Withdrawal Syndrome)































































Two Additional Cases 67 year old female 25 year old medical professional • chronic depression (persistent) depressed 10 years over 12 years • 30-40 ECT no help • 12 ECT no help, some • MAOI selegeline at highest dose improvement with Abilify plus all SSRIs, SNRIs, TCA. • PPX – able to have sexual orgasm • Had plan to suicide with helium for first time since highest dose canister. depressed. Was told his case was "hopeless". • Able to laugh and joke. • PHQ-9 score from 26 to 6 in 6 Full remission. weeks. No suicide plan.









Experience with Pramipexole (PPX)

Dose tolerance/requirements increases with age:

- 30's 0.5-2.5 mg
- 6o's 3.0-5.0 mg tolerated and required for response

Rate of increase balanced against time needed for response.

Nausea and sleepiness may remit over 7 days.

Give total dose at night – pts. have more SE and reject it when given during daytime.

Dose required for response/ tolerance highly variable

Does it work better with noradrenergic ADM's?

Patient failing stimulants may respond after PP

Patients may become more sensitive to dose, and discontinue over time –even without relapse – maybe dose can be decreased over time?

PPX is neuroprotective and neurorestorative – causes regrowth of DA neurons.

Pramipexole


Aiken CB, J. Clin Psychiatry – Pramipexole Review


- reviewed 24 out of 500 articles: large effect size (.6-`1.0) in the treatment of both bipolar and unipolar disorder.
- Low rate of manic switching.
- Pooled discontinuation rate 9%
- Neuroprotective and beneficial effects on sleep architecture

Side Effects

- sleep attacks
- compulsive behaviors and pathological gambling reported in Parkinson, restless legs syndrome and psychosis in psychiatric and Parkinson's disease.
- Dose tolerance seems higher as age is higher.
- Most TRMD responders at 3-5 mg given qhs. < 35 more SE nausea, profound tiredness, response as low as 0.5 mg. 84 year old patient –response peak a 5.0 mg qhs.

Personal Experience





Summary

Six cases of Treatment Refractory Depression

- failure of at least 3 NGA plus augmentation, TCA trial, and at least two ECT trials - are presented who received a sustained recovery
- over 2-4 years in 4 cases
- 12 months and counting in one case
- one case just responded

One case responded to phenelezine plus methylphenidate and

 five responded to pramipexole (PPX) plus either venlafaxanie or clomipramine and methylphenidate.

Two patients may have experienced decline of anxiety severity.

It appears that dopamine active medications are limited to a few and may be likely to be effective in TRMD.

 They seem to increase pleasure seeking behavior more an other ADMs-This may be why they are particularly effective – other commonly used antidepressants target serotonin (SSRIs), or norepinephrine (SNRIs) or both, but not dopamine(DA) function.